What is Opuntia ficus-indica?
The prickly pear cactus — Opuntia ficus-indica — is a cactus species originally from Mexico, long cultivated throughout the Mediterranean. It is among the more well-studied plants in the supplement category, with active compounds including flavonoids, betalains, and pectins.
It is important to distinguish which part of the plant is being studied. The clinical research most relevant here uses extracts from cladodes — the flat, paddle-like stem segments — not the fruit. The extract used in research is sometimes sold under the trade name Tex-OE.
What the research shows — honestly
The most cited study
The clinical trial that brought Opuntia into focus was published in 2004 in Archives of Internal Medicine by Wiese et al. It was a randomised, double-blind, placebo-controlled crossover study involving 64 healthy adults. Participants received either Opuntia extract or placebo five hours before alcohol consumption.
The results were clear on specific outcomes: the proportion of participants reporting severe hangover was 50% lower in the Opuntia group than the placebo group. The proportion reporting nausea, dry mouth, and loss of appetite was significantly lower. However, no significant difference was found for other classic symptoms such as headache, fatigue, and dizziness.
That is a meaningful finding. But it is one study, using a specific extract, under a specific protocol, on 64 people. It is not sufficient evidence that Opuntia cures or prevents hangovers — it is an early result pointing to a mechanism worth investigating further, not an established fact.
The proposed mechanism
Alcohol triggers an inflammatory response in the body. When the liver breaks down alcohol, it produces acetaldehyde and reactive oxygen species that damage cells and trigger an inflammatory cascade. The flavonoids and betacyanins in Opuntia have antioxidant properties studied in several in vitro contexts, and the researchers behind the Wiese study propose this as a possible explanation for their results. That remains a hypothesis rather than a proven causal link — and even if it were proven, it wouldn't automatically entitle us to market a health claim around it.
What EU regulation allows us to say
Opuntia ficus-indica, like milk thistle, has "on-hold" status with EFSA. That means the authority is still evaluating the substance, and no specific health claim — about hangovers, hydration, or inflammation — is approved for marketing within the EU. The April 2025 ruling applies here too: promising individual research doesn't entitle us to make effect claims in marketing.
What we can say, honestly: Opuntia appears in traditional use in arid climates, and one published clinical study has looked at it in an alcohol context with interesting but limited results. The 200 mg dose in HANGOVR GUARD matches the one used in that study. It's included as a traditionally used botanical extract at a research-aligned dose — not as a claimed cure.
Summary
- →Opuntia ficus-indica is among the more clinically studied ingredients in this category
- →Wiese et al. (2004): 50% lower reported severe hangover in a 64-person study — an early finding, not a proven cure
- →EFSA classifies Opuntia as "on-hold" — no health claims are approved, so we make none
- →200 mg in HANGOVR GUARD matches the clinical dosing, as a traditional botanical extract
Frequently asked questions
What is Opuntia ficus-indica? +
Opuntia ficus-indica is the prickly pear cactus — originally from Mexico, long cultivated across the Mediterranean. Extracts from its cladodes (flat pads) are used in supplements for their flavonoids, betalains, and pectins.
What does the clinical study on Opuntia and hangovers show? +
In a randomised, double-blind study (Wiese et al., 2004, Archives of Internal Medicine), 50% fewer participants in the Opuntia group reported severe hangover compared to placebo, with significantly fewer reporting nausea, dry mouth, and loss of appetite. No EU health claim exists for Opuntia.
Why is it included in HANGOVR GUARD? +
Opuntia has more human research in this context than most ingredients in the category, and the 200 mg dose follows the clinically studied amount. But EFSA classifies it as "on-hold," so we make no effect claims about it — it's included as a traditionally used botanical extract at a research-aligned dose.